AccScience Publishing / HM / Online First / DOI: 10.36922/HM026350014
Cite this article
3
Download
34
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
REVIEW ARTICLE

Targeting the hypoxia paradox in neurodegeneration: A pharmacological roadmap across PHD inhibitors, HIF stabilizers, and stage-selective interventions

Manojkumar S. Mahajan1 ,  Aman B. Upaganlawar1 ,  Chandrashekhar D. Upasani1*
Show Less
1 Department of Pharmacology, SNJB’s Shriman Sureshdada Jain College of Pharmacy, Chandwad, Savitribai Phule Pune University, Pune, Maharashtra , India
Received: 25 August 2026 | Revised: 22 September 2026 | Accepted: 8 October 2026 | Published online: 17 November 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Hypoxia-inducible factor (HIF) signaling shows a dual, stage-dependent effect in the nervous system. Acute or mild oxygen deprivation activates HIF-1α-dependent programs that protect neurons; chronic or severe hypoxic stress turns the same pathway into a driver of mitochondrial dysfunction, oxidative injury, and neurodegeneration. This duality appears across Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and cerebral ischemia, and recent reviews have mapped its molecular determinants in detail. Building on this mechanistic foundation, we present a therapeutics-oriented account of how such staging could inform drug selection, framed as a hypothesis-generating translational framework rather than a validated clinical strategy. After summarizing the evidence for stage-dependent HIF signaling, we evaluated the pharmacological toolkit available or in development to act on it: prolyl hydroxylase domain inhibitors such as roxadustat, vadadustat, and daprodustat, developed for renal anemia and now candidates for neurological repurposing; selective HIF-2α antagonism, exemplified by the oncology drug belzutifan, proposed as an exploratory strategy for chronic-stage exposure; non-pharmacological hypoxic conditioning protocols; and adjunct strategies targeting phosphate and Tensin homolog-induced kinase 1/Parkin-dependent mitophagy. We reviewed clinical trial evidence on efficacy and on cardiovascular, hematologic, and oncologic safety, and outlined translational barriers still facing neurological application: blood–brain barrier penetration, the lack of biomarkers that can independently stage a patient’s hypoxic status, and the disappointing history of erythropoietin-based neuroprotection trials. We concluded with a conceptual roadmap for stage-selective research and identified the biomarker and trial-design work needed before pharmacological modulation of this HIF duality can be explored rationally in neurodegenerative disease.

Keywords
Hypoxia-inducible factor
Neurodegeneration
Prolyl hydroxylase inhibitor
HIF-2α antagonist
Mitophagy
Alzheimer’s disease
Parkinson’s disease
Amyotrophic lateral sclerosis
Funding
This study received no external funding.
Conflict of interest
The authors declare no conflicts of interest.
References

Abdulkhaliq, A. A., Kim, B., Almoghrabi, Y. M., Khan, J., Ajoolabady, A., Ren, J., Bahijri, S., Tuomilehto, J., Borai, A., & Pratico, D. (2026). Amyloid-β and Tau in Alzheimer’s disease: Pathogenesis, mechanisms, and interplay. Cell Death & Disease, 17(1), Article 21. https://doi.org/10.1038/s41419-025-08186-8

 

Aderinto, N., Mbah, E. C., Halimat, A. A., Kolo, R. M., Tembo, W., Arumugam, H. K., Javed, A., Akinbo, O. E., Olalusi, M. P., & Egwu, E. O. (2026). Cerebrovascular Disease in Amyotrophic Lateral Sclerosis: Epidemiology, Mechanisms, and Clinical Implications. Sclerosis, 4(3), 18. https://doi.org/10.3390/sclerosis4030018

 

Bartnicki, P. (2024). Hypoxia-inducible factor prolyl hydroxylase inhibitors as a new treatment option for anemia in chronic kidney disease. Biomedicines, 12(8), 1884. https://doi.org/10.3390/biomedicines12081884

 

Bayne, A. N., & Trempe, J.-F. (2026). Molecular mechanisms of PINK1/Parkin-mediated mitochondrial quality control. Trends in Biochemical Sciences, 51(5), 474–490. https://doi.org/10.1016/j.tibs.2026.02.014

 

Blagov, A. V., Goncharov, A. G., Babich, O. O., Larina, V. V., Orekhov, A. N., & Melnichenko, A. A. (2022). Prospects for the development of Pink1 and Parkin activators for the treatment of Parkinson’s disease. Pharmaceutics, 14(11), 2514. https://doi.org/10.3390/pharmaceutics14112514

 

Boulares, A., Pichon, A., Faucher, C., Bragazzi, N. L., & Dupuy, O. (2024). Effects of intermittent hypoxia protocols on cognitive performance and brain health in older adults across cognitive states: A systematic literature review. Journal of Alzheimer’s Disease, 101(1), 13–30. https://doi.org/10.3233/JAD-240711

 

Burtscher, J., Duderstadt, Y., Gatterer, H., Burtscher, M., Vozdek, R., Millet, G. P., Hicks, A. A., Ehrenreich, H., & Kopp, M. (2024). Hypoxia sensing and responses in Parkinson’s disease. International Journal of Molecular Sciences, 25(3), 1759. https://doi.org/10.3390/ijms25031759

 

Camberos-Barraza, J., Alemán-Villa, K. M., & De la Herrán-Arita, A. K. (2026). Hypoxia, sleep architecture, and brain clearance: Converging pathways in neurodegenerative disease. Hypoxia Med, 026110001. https://doi.org/10.36922/HM026110001

 

Campla, C., Hoppe, G., Yu, M., Woda, J., Peachey, N. S., Josyula, V. P., Stauffer, S. R., & Sears, J. E. (2025). Characterization of hepatotropic small molecule inhibitors of hypoxia inducible factor prolyl hydroxylase in the prevention of oxygen-induced retinopathy. Journal of Medicinal Chemistry, 68(12), 12392–12401. https://doi.org/10.1021/acs.jmedchem.4c02186

 

Chang, W.-T., Lo, Y.-C., Gao, Z.-H., & Wu, S.-N. (2019). Evidence for the capability of roxadustat (FG-4592), an oral HIF prolyl-hydroxylase inhibitor, to perturb membrane ionic currents: An unidentified yet important action. International Journal of Molecular Sciences, 20(23), 6027. https://doi.org/10.3390/ijms20236027

 

Chen, D., Niu, Y., Liu, F., Yang, Y., Wang, X., Li, P., & Chen, X. (2023). Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: A systematic review and network meta-analysis. Frontiers in Pharmacology, 14, 1163908. https://doi.org/10.3389/fphar.2023.1163908

 

Chen, R. L., Ogunshola, O. O., Yeoh, K. K., Jani, A., Papadakis, M., Nagel, S., Schofield, C. J., & Buchan, A. M. (2014). HIF prolyl hydroxylase inhibition prior to transient focal cerebral ischaemia is neuroprotective in mice. Journal of Neurochemistry, 131(2), 177–189. https://doi.org/10.1111/jnc.12804

 

Chertow, G. M., Pergola, P. E., Farag, Y. M. K., Agarwal, R., Arnold, S., Bako, G., Block, G. A., Burke, S., Castillo, F. P., Jardine, A. G., Khawaja, Z., Koury, M. J., Lewis, E. F., Lin, T., Luo, W., Maroni, B. J., Matsushita, K., McCullough, P. A., Parfrey, P. S., … Eckardt, K.-U. (2021). Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD. New England Journal of Medicine, 384(17), 1589–1600. https://doi.org/10.1056/nejmoa2035938

 

Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., Wallace, E. M., & Kaelin, W. G., Jr. (2016). On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature, 539(7627), 107–111. https://doi.org/10.1038/nature19795

 

Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., Zojwalla, N. J., & Jonasch, E. (2021a). Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: A phase 1 trial and biomarker analysis. Nature Medicine, 27(5), 802–805. https://doi.org/10.1038/s41591-021-01324-7

 

Choueiri, T. K., Powles, T., Burotto, M., Escudier, B., Bourlon, M. T., Zurawski, B., Oyervides Juárez, V. M., Hsieh, J. J., Basso, U., Shah, A. Y., Suárez, C., Hamzaj, A., Goh, J. C., Barrios, C., Richardet, M., Porta, C., Kowalyszyn, R., Feregrino, J. P., Żołnierek, J., … Motzer, R. J. (2021b). Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 384(9), 829–841. https://doi.org/10.1056/nejmoa2026982

 

Correia, S. C., Carvalho, C., Cardoso, S., et al. (2013). Defective HIF signaling pathway and brain response to hypoxia in neurodegenerative diseases: Not an “iffy” question! Current Pharmaceutical Design, 19(38), 6809–6822. https://doi.org/10.2174/1381612811319380013

 

Deeks, E. D. (2021). Belzutifan: First approval. Drugs, 81(16), 1921–1927. https://doi.org/10.1007/s40265-021-01606-x

 

Del Balzo, U., Signore, P. E., Walkinshaw, G., Seeley, T. W., Brenner, M. C., Wang, Q., Guo, G., Arend, M. P., Flippin, L. A., Chow, F. A., Gervasi, D. C., Kjaergaard, C. H., Langsetmo, I., Guenzler, V., Liu, D. Y., Klaus, S. J., Lin, A., & Neff, T. B. (2020). Nonclinical characterization of the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat, a novel treatment of anemia of chronic kidney disease. Journal of Pharmacology and Experimental Therapeutics, 374(2), 342–353. https://doi.org/10.1124/jpet.120.265181

 

Devarasetty, P. P., Kunte, S. J., Dada, O., & Sparkle, T. (2022). Roxadustat: A narrative review of action and safety profile. J Anesth Clin Care, 9(1), 1-8. https://doi.org/10.24966/ACC-8879/100072

 

Dirnagl, U., Becker, K., & Meisel, A. (2009). Preconditioning and tolerance against cerebral ischaemia: From experimental strategies to clinical use. The Lancet Neurology, 8(4), 398–412. https://doi.org/10.1016/S1474-4422(09)70054-7

 

Eckardt, K.-U., Agarwal, R., Aswad, A., Awad, A., Block, G. A., Bacci, M. R., Farag, Y. M. K., Fishbane, S., Hubert, H., Jardine, A., Khawaja, Z., Koury, M. J., Maroni, B. J., Matsushita, K., McCullough, P. A., Lewis, E. F., Luo, W., Parfrey, P. S., Pergola, P., … Chertow, G. M. (2021a). Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. New England Journal of Medicine, 384(17), 1601–1612. https://doi.org/10.1056/nejmoa2025956

 

Eckardt, K.-U., Agarwal, R., Farag, Y. M. K., Jardine, A. G., Khawaja, Z., Koury, M. J., Luo, W., Matsushita, K., McCullough, P. A., Parfrey, P. S., Pergola, P. E., Roy-Chaudhury, P., Sarnak, M. J., Sharma, A., Spinowitz, B., Tumlin, J., Vargo, D. L., Walters, K. A., Winkelmayer, W. C., Chertow, G. M. (2021b). Global phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: Rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials. Nephrology Dialysis Transplantation, 36(11), 2039–2048. https://doi.org/10.1093/ndt/gfaa204

 

Ehrenreich, H., Kästner, A., Weissenborn, K., Streeter, J., Sperling, S., Wang, K. K. W., Worthmann, H., Hayes, R. L., von Ahsen, N., Kastrup, A., Jeromin, A., & Herrmann, M. (2011). Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients. Molecular Medicine, 17(11–12), 1306–1310. https://doi.org/10.2119/molmed.2011.00259

 

Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P. D., Bohn, M., Becker, H., Wegrzyn, M., Jähnig, P., Herrmann, M., Knauth, M., Bähr, M., Heide, W., Wagner, A., Schwab, S., Reichmann, H., Schwendemann, G., … Bartels, C. (2009). Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke. Stroke, 40(12). https://doi.org/10.1161/strokeaha.109.564872

 

Engelhardt, S., Patkar, S., & Ogunshola, O. O. (2014). Cell-specific blood-brain barrier regulation in health and disease: a focus on hypoxia. British Journal of Pharmacology, 171(5), 1210–1230. https://doi.org/10.1111/bph.12489

 

Fu, Z., Geng, X., Chi, K., Song, C., Wu, D., Liu, C., & Hong, Q. (2022). Efficacy and safety of daprodustat vs rhEPO for anemia in patients with chronic kidney disease: A meta-analysis and trial sequential analysis. Frontiers in Pharmacology, 13, 746265. https://doi.org/10.3389/fphar.2022.746265

 

Fujimaki, A., Ohuchi, K., Takizawa, S., Murakami, T., Kurita, H., Hozumi, I., Wen, X., Kitamura, Y., Wu, Z., Maekawa, Y., & Inden, M. (2023). The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-023-42903-7

 

Gaetani, L., Paolini Paoletti, F., Bellomo, G., Mancini, A., Simoni, S., Di Filippo, M., & Parnetti, L. (2020). CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. Trends in Pharmacological Sciences, 41(12), 1023–1037. https://doi.org/10.1016/j.tips.2020.09.011

 

Gallez, B. (2022). The role of imaging biomarkers to guide pharmacological interventions targeting tumor hypoxia. Frontiers in Pharmacology, 13, 853568. https://doi.org/10.3389/fphar.2022.853568

 

Gao, Y., Zhang, J., Tang, T., & Liu, Z. (2024). Hypoxia pathways in Parkinson’s disease: From pathogenesis to therapeutic targets. International Journal of Molecular Sciences, 25(19), 10484. https://doi.org/10.3390/ijms251910484

 

Haase V. H. (2013). Regulation of erythropoiesis by hypoxia-inducible factors. Blood reviews, 27(1), 41–53. https://doi.org/10.1016/j.blre.2012.12.003

 

Hirota, K. (2021). HIF-α prolyl hydroxylase inhibitors and their implications for biomedicine: A comprehensive review. Biomedicines, 9(5), 468. https://doi.org/10.3390/biomedicines9050468

 

Huang, X., Zhao, L., & Peng, R. (2022). Hypoxia-inducible factor 1 and mitochondria: An intimate connection. Biomolecules, 13(1), 50. https://doi.org/10.3390/biom13010050

 

Imai, E., & Imai, A. (2024). The comparison between vadadustat and daprodustat regarding dose, cost, and safety of treatment for renal anemia in non-dialysis patients with chronic kidney diseases. Intern Med, 63(13), 1841–1848. https://doi.org/10.2169/internalmedicine.2501-23

 

Jiang, B., Wang, X., Ma, J., Fayyaz, A., Wang, L., Qin, P., Ding, Y., Ji, X., & Li, S. (2024). Remote ischemic conditioning after stroke: Research progress in clinical study. CNS Neurosci Ther, 30(4), e14507. https://doi.org/10.1111/cns.14507

 

Jiang, B. H., & Hassan, K. (2026). Hypoxia-inducible factor 1 alpha in cancer: Discovery, regulation, mechanism, and clinical impact. Hypoxia Med, HM025520004. https://doi.org/10.36922/HM025520004

 

Johnson, H. N., & Prasad-Reddy, L. (2025). Daprodustat: A hypoxia-inducible factor-prolyl hydroxylase inhibitor for anemia of chronic kidney disease. The Annals of Pharmacotherapy, 59(1), 71–80. https://doi.org/10.1177/10600280241241563

 

Kaelin, W. G., Jr. (2022). Von Hippel-Lindau disease: Insights into oxygen sensing, protein degradation, and cancer. Journal of Clinical Investigation, 132(18), e162480. https://doi.org/10.1172/JCI162480

 

Kittur, F. S., Hung, C.-Y., Li, P.-A., Sane, D. C., & Xie, J. (2023). Asialo-rhuEPO as a potential neuroprotectant for ischemic stroke treatment. Pharmaceuticals (Basel), 16(4), 610. https://doi.org/10.3390/ph16040610

 

Kucharczyk, J., Bhatt, A., Bauer, L., & Economides, M. (2025). Belzutifan-associated hypoxia: A review of the novel therapeutic, proposed mechanisms of hypoxia, and management recommendations. International Journal of Molecular Sciences, 26(15), 7094. https://doi.org/10.3390/ijms26157094

 

Lei, L., Feng, J., Wu, G., Wei, Z., Wang, J. Z., Zhang, B., Liu, R., Liu, F., Wang, X., & Li, H. L. (2022). HIF-1α causes LCMT1/PP2A deficiency and mediates tau hyperphosphorylation and cognitive dysfunction during chronic hypoxia. International Journal of Molecular Sciences, 23(24), 16140. https://doi.org/10.3390/ijms232416140

 

Li, J., Yang, D., Li, Z., Zhao, M., Wang, D., Sun, Z., Wen, P., Dai, Y., Gou, F., Ji, Y., Zhao, D., & Yang, L. (2023). PINK1/Parkin-mediated mitophagy in neurodegenerative diseases. Ageing Research Reviews, 84, 101817. https://doi.org/10.1016/j.arr.2022.101817

 

Li, Y., Xu, Z., Tian, Z., Guo, M., Shao, Q., Liu, Y., Gu, Y., Jin, F., Ji, X., & Liu, J. (2026). Novel mechanism of neuronal hypoxia response: HIF-1α/STOML2-mediated PINK1-dependent mitophagy activation against neuronal injury. Cell Death Discovery, 12(1), 104. https://doi.org/10.1038/s41420-026-02960-z

 

Liu, B., Li, M., Zhang, L., Chen, Z., & Lu, P. (2022). Motor neuron replacement therapy for amyotrophic lateral sclerosis. Neural Regeneration Research, 17(8), 1633–1639. https://doi.org/10.4103/1673-5374.332123

 

Liu, C., He, W., & Zhang, J. (2025). Exercise regulates mitophagy to alleviate parkinsonian neurodegeneration. Frontiers in Aging Neuroscience, 17, 1678460. https://doi.org/10.3389/fnagi.2025.1678460

 

Lo, E., Cizmeci, M. N., Wilson, D., Ly, L. G., El-Shahed, A., Offringa, M., Pierro, A., & Kalish, B. T. (2025). Remote ischemic post-conditioning for neonatal encephalopathy: A safety and feasibility trial. Pediatric Research, 97(6), 1966–1975. https://doi.org/10.1038/s41390-024-03625-2

 

López-Hernández, B., Posadas, I., Podlesniy, P., Abad, M. A., Trullas, R., & Ceña, V. (2012). HIF-1α is neuroprotective during the early phases of mild hypoxia in rat cortical neurons. Experimental Neurology, 233(1), 543–554. https://doi.org/10.1016/j.expneurol.2011.11.040

 

Mendelson, S. J., & Prabhakaran, S. (2021). Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke: A Review. JAMA, 325(11), 1088–1098. https://doi.org/10.1001/jama.2020.26867

 

Miao, M., Wu, M., Li, Y., Zhang, L., Jin, Q., Fan, J., Xu, X., Gu, R., Hao, H., Zhang, A., & Jia, Z. (2022). Clinical potential of hypoxia inducible factor prolyl hydroxylase inhibitors in treating nonanemic diseases. Frontiers in Pharmacology, 13, 837249. https://doi.org/10.3389/fphar.2022.837249

 

Mikitsh, J. L., & Chacko, A. M. (2014). Pathways for small molecule delivery to the central nervous system across the blood-brain barrier. Perspectives in Medicinal Chemistry, 6, 11–24. https://doi.org/10.4137/PMC.S13384

 

Minutolo, R., Liberti, M. E., Simeon, V., Sasso, F. C., Borrelli, S., De Nicola, L., & Garofalo, C. (2024). Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: Meta-analysis of phase 3 randomized controlled trials. Clinical Kidney Journal, 17(1), sfad143. https://doi.org/10.1093/ckj/sfad143

 

Mitroshina, E. V., Strelkova, P. L., Korokozova, M. V., & Vedunova, M. V. (2026). HIF1 stabilization by roxadustat improves cognition and prevents neuron loss in Alzheimer’s disease in vivo. Biology (Basel), 15(14), 1118. https://doi.org/10.3390/biology15141118

 

Moreau, C., Gosset, P., Kluza, J., Brunaud-Danel, V., Lassalle, P., Marchetti, P., Defebvre, L., Destée, A., & Devos, D. (2011). Deregulation of the hypoxia inducible factor-1α pathway in monocytes from sporadic amyotrophic lateral sclerosis patients. Neuroscience, 172, 110–117. https://doi.org/10.1016/j.neuroscience.2010.10.040

 

Narendra, D. P., & Youle, R. J. (2024). The role of PINK1-Parkin in mitochondrial quality control. Nature Cell Biology, 26(10), 1639–1651. https://doi.org/10.1038/s41556-024-01513-9

 

Nyamukondiwa, M., Koneva, E. S., Achkasov, E. E., Zhang, X., Y, P. R., Beeraka, N. M., & Glazachev, O. S. (2025). Exploring hypoxia-induced neuroprotection mechanisms in post-stroke recovery. Translational Stroke Research, 16(6), 2298–2324. https://doi.org/10.1007/s12975-025-01364-y

 

Ogunshola, O. O., & Antoniou, X. (2009). Contribution of hypoxia to Alzheimer’s disease: is HIF-1alpha a mediator of neurodegeneration?. Cellular and Molecular Life Sciences, 66(22), 3555–3563. https://doi.org/10.1007/s00018-009-0141-0

 

Packer M. (2020). Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders. JACC. Basic to Translational Science, 5(9), 961–968. https://doi.org/10.1016/j.jacbts.2020.05.006

 

Pérez-Mato, M., López-Arias, E., Bugallo-Casal, A., Correa-Paz, C., Arias, S., Rodríguez-Yáñez, M., Santamaría-Cadavid, M., & Campos, F. (2024). New perspectives in neuroprotection for ischemic stroke. Neuroscience, 550, 30–42. https://doi.org/10.1016/j.neuroscience.2024.02.017

 

Porel, P., Bala, K., & Aran, K. R. (2025). Exploring the role of HIF-1α on pathogenesis in Alzheimer’s disease and potential therapeutic approaches. Inflammopharmacology, 33(2), 669–678. https://doi.org/10.1007/s10787-024-01585-x

 

Provenzano, R., Szczech, L., Leong, R., Saikali, K. G., Zhong, M., Lee, T. T., Little, D. J., Houser, M. T., Frison, L., Houghton, J., & Neff, T. B. (2021). Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non–Dialysis-Dependent CKD. Clinical Journal of the American Society of Nephrology, 16(8), 1190–1200. https://doi.org/10.2215/cjn.16191020

 

Purroy, F., Beretta, S., England, T. J., Hess, D. C., Pico, F., & Shuaib, A. (2022). Editorial: Remote ischemic conditioning (pre, per, and post) as an emerging strategy of neuroprotection in ischemic stroke. Frontiers in Neurology, 13, 932891. https://doi.org/10.3389/fneur.2022.932891

 

Puthusseri, S. P., Ravivarma, S., Johny, M., & Vengellur, A. (2026). Hypoxia-inducible factor-1α: Dual roles in maintaining neuronal homeostasis and neuronal degeneration via regulation of oxidative stress, mitochondrial dynamics, and bioenergetics. Journal of Physiology and Biochemistry, 82(1), 47. https://doi.org/10.1007/s13105-026-01187-x

 

Randy, H., Perrin, T. P., Ghaith, A., Kohlbrenner, D., Flore, P., Champigneulle, B., Guinot, M. F., Doutreleau, S., Verges, S., Brugniaux, J. V., & Marillier, M. (2025). Moderate intermittent hypoxic conditioning to enhance cerebrovascular function in the elderly: A randomized controlled trial. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 329(5), R805–R812. https://doi.org/10.1152/ajpregu.00160.2025

 

Reischl, S., Li, L., Walkinshaw, G., Flippin, L. A., Marti, H. H., & Kunze, R. (2014). Inhibition of HIF prolyl-4-hydroxylases by FG-4497 reduces brain tissue injury and edema formation during ischemic stroke. PLOS ONE, 9(1), e84767. https://doi.org/10.1371/journal.pone.0084767

 

Ren, X., Diao, X., Zhuang, J., & Wu, D. (2022). Structural basis for the allosteric inhibition of hypoxia-inducible factor (HIF)-2 by belzutifan. Molecular Pharmacology, 102(6), 240–247. https://doi.org/10.1124/molpharm.122.000525

 

Rosencrans, W. M., Lee, R. W., McGraw, L., Horsburgh, I., Wang, T.-Y., Quan, B., Huynh, D., Johnston, J. A., Chan, D. C., & Chou, T.-F. (2025). Putative PINK1/Parkin activators lower the threshold for mitophagy by sensitizing cells to mitochondrial stress. Science Advances, 11(35), eady0240. https://doi.org/10.1126/sciadv.ady0240

 

Sajjadi, E., Seven, Y. B., Ehrbar, J. G., Wymer, J. P., Mitchell, G. S., & Smith, B. K. (2022). Acute intermittent hypoxia and respiratory muscle recruitment in people with amyotrophic lateral sclerosis: A preliminary study. Experimental Neurology, 347, 113890. https://doi.org/10.1016/j.expneurol.2021.113890

 

Serebrovska, Z., Xi, L., Khetsuriani, M., Protsenko, O., Morozova, N., Tolstun, D. A., & Maksymchuk, O. (2025). Utility of Drosophila for studying hypoxia-inducible factor (HIF) in neurodegenerative diseases: Advantages versus limitations. Brain Research, 1867, 149953. https://doi.org/10.1016/j.brainres.2025.149953

 

Sharp, F. R., Ran, R., Lu, A., Tang, Y., Strauss, K. I., Glass, T., Ardizzone, T., & Bernaudin, M. (2004). Hypoxic preconditioning protects against ischemic brain injury. NeuroRx, 1(1), 26–35. https://doi.org/10.1602/neurorx.1.1.26

 

Singh, A. K., Carroll, K., McMurray, J. J. V., Solomon, S., Jha, V., Johansen, K. L., Lopes, R. D., Macdougall, I. C., Obrador, G. T., Waikar, S. S., Wanner, C., Wheeler, D. C., Więcek, A., Blackorby, A., Cizman, B., Cobitz, A. R., Davies, R., DiMino, T. L., Kler, L., … Perkovic, V. (2021). Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. New England Journal of Medicine, 385(25), 2313–2324. https://doi.org/10.1056/nejmoa2113380

 

Soares, P., Silva, C., Chavarria, D., Silva, F. S. G., Oliveira, P. J., & Borges, F. (2023). Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and therapeutic opportunities. Ageing Research Reviews, 83, 101790. https://doi.org/10.1016/j.arr.2022.101790

 

Souvenir, R., Doycheva, D., Zhang, J. H., & Tang, J. (2015). Erythropoietin in stroke therapy: Friend or foe. Current Medicinal Chemistry, 22(10), 1205–1213. https://doi.org/10.2174/0929867322666150114152134

 

Stoumpos, S., Crowe, K., Sarafidis, P., Barratt, J., Bolignano, D., Del Vecchio, L., Małyszko, J., Więcek, A., Ortiz, A., & Cozzolino, M. (2024). Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: A clinical practice document by the European Renal Best Practice board of the European Renal Association. Nephrology Dialysis Transplantation, 39(10), 1710–1730. https://doi.org/10.1093/ndt/gfae075

 

Su, X., Xie, Y., Zhang, J., Li, M., Zhang, Q., Jin, G., & Liu, F. (2022). HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by inducing ferroptosis. Cell Death & Disease, 13(10), 861. https://doi.org/10.1038/s41419-022-05304-8

 

Sugahara, M., Tanaka, T., & Nangaku, M. (2017). Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney International, 92(2), 306–312. https://doi.org/10.1016/j.kint.2017.02.035

 

Tada, S., Okuno, T., Shimizu, M., Sakai, Y., Sumi-Akamaru, H., Kinoshita, M., Yamashita, K., Sanda, E., Choong, C.-J., Namba, A., Sasaki, T., Koda, T., Takata, K., Miyagawa, S., Sawa, Y., Nakatsuji, Y., & Mochizuki, H. (2019). Single injection of sustained-release prostacyclin analog ONO-1301-MS ameliorates hypoxic toxicity in the murine model of amyotrophic lateral sclerosis. Scientific Reports, 9(1), 5252. https://doi.org/10.1038/s41598-019-41771-4

 

Tao, B., Gong, W., Xu, C., Ma, Z., Mei, J., & Chen, M. (2024). The relationship between hypoxia and Alzheimer’s disease: An updated review. Frontiers in Aging Neuroscience, 16, 1402774. https://doi.org/10.3389/fnagi.2024.1402774

 

Tashima, T. (2023). Proteolysis-targeting chimera (PROTAC) delivery into the brain across the blood-brain barrier. Antibodies (Basel), 12(3), 43. https://doi.org/10.3390/antib12030043

 

Timon, R., Martinez-Guardado, I., & Brocherie, F. (2023). Effects of intermittent normobaric hypoxia on health-related outcomes in healthy older adults: A systematic review. Sports Medicine - Open, 9(1), 19. https://doi.org/10.1186/s40798-023-00560-0

 

Tsai, T.-H., Lu, C.-H., Wallace, C. G., Chang, W.-N., Chen, S.-F., Huang, C.-R., Tsai, N.-W., Lan, M.-Y., Sung, P.-H., Liu, C.-F., & Yip, H.-K. (2015). Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: A randomized, prospective, placebo-controlled clinical trial. Critical Care, 19(1), 49. https://doi.org/10.1186/s13054-015-0761-8

 

Wang, H., Shi, X., Schenck, H., Hall, J. R., Ross, S. E., Kline, G. P., Chen, S., Mallet, R. T., & Chen, P. (2020). Intermittent hypoxia training for treating mild cognitive impairment: A pilot study. Am Journal of Alzheimer’s Disease Other Demen, 35, 1533317519896725. https://doi.org/10.1177/1533317519896725

 

Wang, L., & Xu, B. (2026). Rethinking PINK1/Parkin-mediated mitophagy in Parkinson’s disease: Functional continuity and activation-clearance uncoupling. Frontiers in Aging Neuroscience, 18, 1865383. https://doi.org/10.3389/fnagi.2026.1865383

 

Wang, Y. Y., Huang, Z. T., Yuan, M. H., Jing, F., Cai, R. L., Zou, Q., Pu, Y. S., Wang, S. Y., Chen, F., Yi, W. M., Zhang, H. J., & Cai, Z. Y. (2021). Role of hypoxia inducible factor-1α in Alzheimer’s disease. Journal of Alzheimer’s Disease, 80(3), 949–961. https://doi.org/10.3233/JAD-201448

 

Wen, H., Zuo, Y., Li, L., Zhan, L., Xue, J., Sun, W., & Xu, E. (2023). Hypoxic postconditioning restores mitophagy against transient global cerebral ischemia via Parkin-induced posttranslational modification of TBK1. Neurobiology of Disease, 179, 106043. https://doi.org/10.1016/j.nbd.2023.106043

 

Wu, X., Lazris, D., Wong, R., & Tykodi, S. S. (2025). Belzutifan for the treatment of renal cell carcinoma. Therapeutic Advances in Medical Oncology, 17, 17588359251317846. https://doi.org/10.1177/17588359251317846

 

Zhang, Q., Wang, Q., Jin, F., Huang, D., Ji, X., & Wang, Y. (2025). Intermittent hypoxia training improves cerebral blood flow without cognitive impairment. Annals of Clinical and Translational Neurology, 12(1), 86–96. https://doi.org/10.1002/acn3.52248

 

Zhang, Z., Yan, J., Chang, Y., ShiDu Yan, S., & Shi, H. (2011). Hypoxia inducible factor-1 as a target for neurodegenerative diseases. Current Medicinal Chemistry, 18(28), 4335–4343. https://doi.org/10.2174/092986711797200426

 

Zhu, L., Su, G., Li, R., Ma, T., Chen, W., Song, J., Wu, Q., An, Y., Wang, C., & Zhang, Z. (2025). The role of hypoxia/ischemia preconditioning in ischemic stroke. Neuroscience, 568, 343–354. https://doi.org/10.1016/j.neuroscience.2025.01.042

Share
Back to top
Hypoxia & Medicine, Published by AccScience Publishing